252 related articles for article (PubMed ID: 26100990)
21. Demographics of apheresis platelet donors in five blood centers in China.
Guo N; Wang J; Ness P; Yao F; Dong X; Bi X; Mei H; Li J; He W; Lu Y; Ma H; Wen X; Huang M; Liu J; Wright DJ; Shan H;
Transfusion; 2012 Mar; 52(3):560-6. PubMed ID: 21895674
[TBL] [Abstract][Full Text] [Related]
22. Delayed adverse events in male plateletpheresis donors: Initial insights on donor safety.
Gupta AM; Bajpai M
J Clin Apher; 2020 Jan; 35(1):18-24. PubMed ID: 31663633
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Fenwal Amicus blood cell separator in double dose platelet collection.
Gürak S; Arslan O
Transfus Apher Sci; 2007 Feb; 36(1):69-72. PubMed ID: 17270496
[TBL] [Abstract][Full Text] [Related]
24. Plateletpheresis donor deferral patterns at a tertiary care hospital in North India: A need for rethink of haemoglobin cutoff.
Sharma H; Khajuria K; Bansal N; Thakur K; Sharma A
Transfus Clin Biol; 2023 May; 30(2):268-271. PubMed ID: 36893913
[TBL] [Abstract][Full Text] [Related]
25. Alarmed or unalarmed!! Donor red cell lysis during plateletpheresis procedure.
Kaur D; Kandwal M
Transfus Apher Sci; 2018 Apr; 57(2):277-280. PubMed ID: 29610044
[TBL] [Abstract][Full Text] [Related]
26. Prevalence and predictors of adverse reactions in plateletpheresis donors with the perspective of donor safety in a tertiary care hospital of Northern India.
Solanki A; Katharia R; Singh A; Chauhan A; Chandra T; Sonker A; Agarwal P
Asian J Transfus Sci; 2020; 14(1):44-48. PubMed ID: 33162705
[TBL] [Abstract][Full Text] [Related]
27. Donor safety in triple plateletpheresis: results from the German and Austrian Plateletpheresis Study Group multicenter trial.
Heuft HG; Moog R; Fischer EG; Zingsem J;
Transfusion; 2013 Jan; 53(1):211-20. PubMed ID: 22612302
[TBL] [Abstract][Full Text] [Related]
28. The impact of immediate adverse donation reactions on the return of volunteers undergoing platelet apheresis.
de Farias CLG; Bassolli L; Mendrone-Junior A; de Araújo Arrais C; Duran A; Rocha V; de Almeida-Neto C
Transfus Apher Sci; 2022 Aug; 61(4):103424. PubMed ID: 35346602
[TBL] [Abstract][Full Text] [Related]
29. Apheresis affects bone and mineral metabolism.
Amrein K; Katschnig C; Sipurzynski S; Stojakovic T; Lanzer G; Stach E; Pieber TR; Dobnig H
Bone; 2010 Mar; 46(3):789-95. PubMed ID: 19922822
[TBL] [Abstract][Full Text] [Related]
30. Successful removal of Chlamydia pneumoniae from plateletpheresis products collected using automated leukoreduction hemapheresis techniques.
Webley W; Stuart E; Cirino F; Cahill F; Stec T; Andrzejewski C
J Clin Apher; 2006 Oct; 21(3):195-201. PubMed ID: 16570261
[TBL] [Abstract][Full Text] [Related]
31. Vasovagal reactions in 'at risk' donors: a univariate analysis of effect of age and weight on the grade of donor reactions.
Tondon R; Pandey P; Chaudhary R
Transfus Apher Sci; 2008 Oct; 39(2):95-9. PubMed ID: 18753009
[TBL] [Abstract][Full Text] [Related]
32. Severe citrate toxicity complicating volunteer apheresis platelet donation.
Bell AM; Nolen JD; Knudson CM; Raife TJ
J Clin Apher; 2007 Feb; 22(1):15-6. PubMed ID: 17111419
[TBL] [Abstract][Full Text] [Related]
33. Clinical and clinicopathologic effects of plateletpheresis on healthy donor dogs.
Callan MB; Appleman EH; Shofer FS; Mason NJ; Brainard BM; Groman RP
Transfusion; 2008 Oct; 48(10):2214-21. PubMed ID: 18564392
[TBL] [Abstract][Full Text] [Related]
34. [Complications of plateletpheresis procedures].
García Gala JM; Rodríguez-Vicente P; Martínez Revuelta E; Alonso García A; Sanzo Lombardero C; Alvarez Ferrando A
Sangre (Barc); 1998 Oct; 43(5):365-70. PubMed ID: 9868326
[TBL] [Abstract][Full Text] [Related]
35. Implications of a switch to a 100% apheresis platelet supply for patients and for blood donors: a risk benefit analysis.
Thiele T; Alt-Mayer T; Greinacher A; Bux J
Vox Sang; 2016 Nov; 111(4):350-356. PubMed ID: 27432635
[TBL] [Abstract][Full Text] [Related]
36. Pre- and post- donation haematological values in healthy donors undergoing plateletpheresis with five different systems.
Das SS; Chaudhary R; Verma SK; Ojha S; Khetan D
Blood Transfus; 2009 Jul; 7(3):188-92. PubMed ID: 19657482
[TBL] [Abstract][Full Text] [Related]
37. Improved donor safety in high-volume apheresis collections.
Vassallo RR; Bravo MD; Kamel H
Transfusion; 2017 Feb; 57(2):319-324. PubMed ID: 27861957
[TBL] [Abstract][Full Text] [Related]
38. Feasibility of applying the 2day deferral for repeat plateletpheresis: Indian perspective.
Nomani L; Raina TR; Sidhu M
Transfus Apher Sci; 2013 Jun; 48(3):341-3. PubMed ID: 23643473
[TBL] [Abstract][Full Text] [Related]
39. First-time whole blood donation: A critical step for donor safety and retention on first three donations.
Gillet P; Rapaille A; Benoît A; Ceinos M; Bertrand O; de Bouyalsky I; Govaerts B; Lambermont M
Transfus Clin Biol; 2015; 22(5-6):312-7. PubMed ID: 26476508
[TBL] [Abstract][Full Text] [Related]
40. The American Red Cross donor hemovigilance program: complications of blood donation reported in 2006.
Eder AF; Dy BA; Kennedy JM; Notari Iv EP; Strupp A; Wissel ME; Reddy R; Gibble J; Haimowitz MD; Newman BH; Chambers LA; Hillyer CD; Benjamin RJ
Transfusion; 2008 Sep; 48(9):1809-19. PubMed ID: 18631167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
